CN117442537A - Anti-wrinkle essence - Google Patents
Anti-wrinkle essence Download PDFInfo
- Publication number
- CN117442537A CN117442537A CN202210840131.5A CN202210840131A CN117442537A CN 117442537 A CN117442537 A CN 117442537A CN 202210840131 A CN202210840131 A CN 202210840131A CN 117442537 A CN117442537 A CN 117442537A
- Authority
- CN
- China
- Prior art keywords
- weight
- polyol
- extract
- oil
- madecassoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001153 anti-wrinkle effect Effects 0.000 title abstract description 8
- 229920005862 polyol Polymers 0.000 claims abstract description 52
- 150000003077 polyols Chemical class 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims abstract description 15
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims abstract description 15
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 15
- 229940090813 madecassoside Drugs 0.000 claims abstract description 15
- 239000012071 phase Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- -1 inositol glycerophosphate choline salt Chemical class 0.000 claims abstract description 6
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 5
- 241000871264 Cardiospermum halicacabum Species 0.000 claims abstract description 5
- 239000004381 Choline salt Substances 0.000 claims abstract description 5
- 244000044554 Elaeagnus pungens Species 0.000 claims abstract description 5
- 235000013935 Elaeagnus pungens Nutrition 0.000 claims abstract description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims abstract description 5
- 241001135917 Vitellaria paradoxa Species 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims abstract description 5
- UVTKBJUOKTXTTO-UHFFFAOYSA-N benzoic acid propanamide Chemical compound C(C1=CC=CC=C1)(=O)O.C(CC)(=O)N UVTKBJUOKTXTTO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940036350 bisabolol Drugs 0.000 claims abstract description 5
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019417 choline salt Nutrition 0.000 claims abstract description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 5
- 229960000367 inositol Drugs 0.000 claims abstract description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940057910 shea butter Drugs 0.000 claims abstract description 5
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims abstract description 5
- 239000008346 aqueous phase Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 abstract description 11
- 230000007794 irritation Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 39
- 235000019198 oils Nutrition 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 238000009472 formulation Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 description 11
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 10
- 229940100554 isononyl isononanoate Drugs 0.000 description 10
- 241000144217 Limnanthes alba Species 0.000 description 9
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 9
- 239000000686 essence Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 2
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 2
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 206010051788 Sticky skin Diseases 0.000 description 2
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 2
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 1
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 244000056974 Adansonia digitata Species 0.000 description 1
- 235000003320 Adansonia digitata Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 235000011236 Persea americana var americana Nutrition 0.000 description 1
- 240000003935 Sclerocarya birrea Species 0.000 description 1
- 235000004517 Sclerocarya birrea Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a cosmetic composition, an anti-wrinkle essence, comprising: an oil phase and an aqueous phase containing a polyol; the weight part of the polyol in the water phase is not less than 10%; a soothing component configured as bisabolol, madecassoside, inositol glycerophosphate choline salt, dipotassium glycyrrhizinate, elaeagnus pungens extract, oxyphenyl propionamide benzoic acid, ginger root extract, shea butter extract, ringer (CARDIOSPERMUM HALICACABUM) flower/leaf/vine extract, and combinations thereof. The active ingredients for inhibiting inflammatory mediators are matched to have more excellent inhibition effect on the irritation caused by the polyalcohol.
Description
Technical Field
The invention relates to the field of anti-wrinkle formulas, in particular to anti-wrinkle essence.
Background
Many of the existing essence on the market are added with peptide in the formula to improve the anti-wrinkle effect of the product. The peptides comprise multiple types, and different types of peptides play a role in resisting wrinkle through different mechanisms, so that most of essences are products matched by the multiple peptides.
Through observation and research by the inventor, the following defects exist in the prior art:
the peptide raw material added into the essence can generate a stimulating sensation when the raw material is high, and the skin feel is poor. It was found that this is due to excessive polyols in the formulation. Firstly, some of the polyol is added to the formulation of most products as a solvent, and secondly, the addition of the peptide material inevitably brings the polyol into the formulation, especially at higher amounts of peptide material. This results in a very high polyol ratio in the higher peptide containing concentrate.
Typically, not too much polyol is added to the cosmetic formulation. Because the polyalcohol has stronger water absorption, the polyalcohol can provide the skin with the functions of water locking and moisture retention. However, when the amount of the polyhydric alcohol added is too high, not only a sticky moist feeling is brought, but also the polyhydric alcohol with too high concentration can generate irritation, and the moisture absorption of the polyhydric alcohol is too good, so that the water content of the skin cuticle can be directly absorbed from the skin, and the skin barrier is damaged.
Disclosure of Invention
The invention aims to solve the technical problems:
how to reduce irritation caused by high levels of polyols.
The technical means for solving the technical problems are as follows:
the invention provides a cosmetic composition, which is characterized by comprising the following components:
a cosmetic composition comprising:
an oil phase and an aqueous phase containing a polyol;
the weight part of the polyol in the water phase is not less than 10%;
a soothing component configured as bisabolol, madecassoside, inositol glycerophosphate choline salt, dipotassium glycyrrhizinate, elaeagnus pungens extract, oxyphenyl propionamide benzoic acid, ginger root extract, shea butter extract, ringer (CARDIOSPERMUM HALICACABUM) flower/leaf/vine extract, and combinations thereof.
Optionally, the soothing component is configured as 0.005 to 0.5% madecassoside by weight.
Optionally, the soothing component is configured as 0.05 to 0.3% madecassoside by weight.
Alternatively, the polyol is configured to be 10 to 20% by weight.
Optionally, the polyol is configured to be 15-20% by weight.
Optionally, the oil phase is configured to be 5-25% by weight.
The polyalcohol such as glycerin has stronger water absorption as a humectant and has the effect of locking water and keeping moisture for skin, but the polyalcohol can bring sticky moist feel, and the content of the polyalcohol added into the cosmetics is not high. When the weight part of the oil is adjusted to be 5-25%, the oil film feel caused by the oil can be reduced, and the oil can be balanced with a large amount of polyol in the formula in skin feel, so that the oil can be used favorably.
Optionally, the oil phase is configured to be 5-15% by weight.
The invention also provides an external skin preparation using any of the cosmetic compositions.
The beneficial effects are that:
in response to the problem of irritation in products containing high levels of peptides, the inventors found that this is due to the excessive levels of polyols, and have unexpectedly found during the course of the study: compared with other soothing components, the active component for inhibiting inflammatory mediators has more effective stimulation inhibition on the stimulation source of the polyol, and particularly has good stimulation inhibition effect when the content of the polyol is high.
The inventors have also found that, in the case of a product containing a high content of peptide, too much polyol causes a problem of sticky skin feel in addition to the irritation, and have found that the problem of sticky skin feel caused by polyol can be improved when the weight part of oil in the product is controlled to be in the range of 5 to 25%.
The invention adds various peptides, and the total content of peptides is very high, which not only ensures the obvious anti-wrinkle effect, but also effectively solves the problem of irritation and skin feel in the high peptide product, improves the anti-wrinkle effect and overcomes the defects of the existing product.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are not all embodiments.
Elements and features described in one embodiment of the invention may be combined with elements and features shown in one or more other embodiments. It should be noted that the illustration and description of components and processes known to those of ordinary skill in the art, which are not relevant to the present invention, have been omitted for clarity.
Definition:
herein, the term "not higher than" means: including cases of less than and equal to.
Herein, the term "not lower" means: including greater than and equal to.
In this context, all parts by weight herein are based on the total weight of the composition of the invention, unless otherwise indicated.
In this context, all ranges defined refer to: including each specific range within a given range as well as combinations of sub-ranges between the given ranges. For example, a range of 1 to 5 specifically includes 1,2, 3, 4 and 5, and also includes sub-ranges such as 2 to 5, 3 to 5, 2 to 3, 2 to 4, 1 to 4, etc.
In this context, the range of ratios refers to: including each specific ratio within a given range and combinations of sub-ranges between the given ranges.
The invention is that
The invention provides a cosmetic composition, which is characterized by comprising the following components:
a cosmetic composition comprising:
an oil phase and an aqueous phase containing a polyol;
the weight part of the polyol in the water phase is not less than 10%;
a soothing component configured as bisabolol, madecassoside, inositol glycerophosphate choline salt, dipotassium glycyrrhizinate, elaeagnus pungens extract, oxyphenyl propionamide benzoic acid, ginger root extract, shea butter extract, ringer (CARDIOSPERMUM HALICACABUM) flower/leaf/vine extract, and combinations thereof.
Optionally, the soothing component is configured as 0.005 to 0.5% madecassoside by weight.
Optionally, the soothing component is configured as 0.05 to 0.3% madecassoside by weight.
Alternatively, the polyol is configured to be 10 to 20% by weight.
Optionally, the polyol is configured to be 15-20% by weight.
Optionally, the oil phase is configured to be 5-25% by weight.
Optionally, the oil phase is configured to be 5-15% by weight.
The invention also provides an external skin preparation using any of the cosmetic compositions. The external preparation comprises toner, eye cream, nourishing cream, massage cream, face cleansing foam, face cleansing water, skin lotion, skin cream, body essence, shampoo, hair conditioner, bath lotion, essence or facial mask or other external skin preparations.
The cosmetic composition according to the present invention may include/may include the following:
polyhydric alcohol
Optionally, the polyol is not more than 20% by weight.
Optionally, the polyol is 10-20% by weight.
The invention is not limited in any way by the specific kind of polyol, and can be reasonably selected according to practical situations when the invention is implemented.
Optionally, the polyol includes 1, 2-hexanediol, glycerol, and 1, 2-pentanediol, and combinations thereof.
Optionally, the polyol comprises: 0.8% of 1, 2-hexanediol, 2% of 1, 2-pentanediol and glycerin.
Soothing component
Optionally, the weight portion of the relieving component is 0.005-0.5%.
Optionally, the weight portion of the relieving component is 0.05 to 0.3 percent.
The soothing component is an active component for inhibiting inflammatory mediators.
The invention does not limit the specific kind of the active ingredients for inhibiting inflammatory mediators, and can be routinely selected according to practical situations when the invention is implemented.
Optionally, the soothing component comprises bisabolol, madecassoside, inositol glycerophosphate choline salt, dipotassium glycyrrhizinate, elaeagnus pungens extract, oxyphenyl propionamide benzoic acid, ginger root extract, shea butter extract, ringer (CARDIOSPERMUM HALICACABUM) flower/leaf/vine extract, and combinations thereof.
In one embodiment, the soothing component is configured to be 0.105% madecassoside by weight.
Oil content
Optionally, the oil content is 5-25% by weight.
In one embodiment, the oil content is 6% by weight.
The invention does not limit the specific types of oil content, and can be reasonably selected according to actual conditions when the invention is implemented.
In one embodiment, the oil comprises coco-caprylate/caprate, caprylic/capric triglyceride, white pool (LIMNANTHES ALBA) seed oil, isononyl isononanoate, avocado (PERSEA GRATISSIMA) oil, squalane, monkey (ADANSONIA DIGITATA) seed oil, berm hard walnut (SCLEROCARYA BIRREA) seed oil, and combinations thereof.
In one embodiment, the oil comprises 2% coco-caprylate/caprate, 2% caprylic/capric triglyceride, 1% white pool (LIMNANTHES ALBA) seed oil, and 1% isononyl isononanoate, by weight.
Preservative agent
Optionally, the preservative is 0.01-3% by weight.
The invention does not limit the specific type of preservative, and can be reasonably selected according to actual conditions when the invention is implemented.
In one embodiment, the preservative comprises 0.4% hydroxyacetophenone by weight.
Thickening agent
Optionally, the weight portion of the thickener is 0.005-2%.
The invention does not limit the specific kind of the thickener, and can be reasonably selected according to actual conditions when the invention is implemented.
Optionally, the thickener comprises xanthan gum, polyacrylate crosslinked polymer-6 and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, carbomer, ammonium polyacryldimethyltaurate, ammonium acryloyldimethyl taurate/VP copolymer, ammonium acryloyldimethyl taurate/behenate polyether-25 methacrylate crosslinked polymer, sodium acrylate copolymer, and combinations thereof.
Alternatively, the thickener comprises 0.05% by weight of xanthan gum, 0.2% of polyacrylate crosslinked polymer-6 and 0.05% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer.
Film forming agent
Optionally, the film forming agent accounts for 0.005-2% by weight.
The invention does not limit the specific types of the film forming agents, and the film forming agents can be reasonably selected according to actual conditions when the invention is implemented.
Optionally, the film former comprises a sclerotium (SCLEROTIUM ROLFSSII) gum, an acrylic/C10-30 alkanol acrylate cross-linked polymer, a castor oil/IPDI copolymer, and combinations thereof.
Optionally, the film former comprises 0.03% by weight castor oil/IPDI copolymer.
PH regulator
Optionally, the weight portion of the pH regulator is 0.001-2%.
The invention does not limit the specific kind of the pH regulator, and can be reasonably selected according to actual conditions when the invention is implemented.
Optionally, the pH adjuster includes citric acid and sodium citrate.
Optionally, the pH adjuster is 0.25% by weight.
Optionally, the pH adjuster comprises 0.2% citric acid and 0.05% sodium citrate by weight.
Peptides
Optionally, the peptide is 5-35% by weight.
The invention is not limited in any way by the specific kind of peptide, and can be reasonably selected according to practical situations when the invention is implemented.
Alternatively, the peptide is selected from the group consisting of dipeptidyl diamino Ding Xianbian amide diacetate, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, acetyl octapeptide-3, palmitoyl tripeptide-5, acetyl pentapeptide-1, acetyl hexapeptide-8, acetyl hexapeptide-3, acetyl hexapeptide-1, and combinations thereof.
Alternatively, the peptide is 20% by weight.
Alternatively, the peptides include, in parts by weight, 5% dipeptide diamino Ding Xianbian base amid diacetate, 2% palmitoyl tetrapeptide-7 and palmitoyl tripeptide-1, 3% acetyl octapeptide-3 and 10% palmitoyl tripeptide-5.
Active material
Optionally, the active is 0.01-10% by weight.
The invention does not limit the specific kind of the active substance, and the active substance can be reasonably selected according to the actual situation when the invention is implemented.
Optionally, the active is selected from arbutin, 3-o-ethyl ascorbic acid, ergothioneine, ectoine, sodium hyaluronate, retinol and its derivatives, plant extracts, licoflavone compounds, and combinations thereof. .
Alternatively, the active is 2.2% by weight.
The preparation method of the invention
The preparation method of the cosmetic composition comprises the following steps:
adding solvent, preservative and thickener into main pot, heating and homogenizing for 10-30 min at 70-85 deg.C, cooling and stirring to 50 deg.C, adding pH regulator and pre-mixed active matter, continuously stirring for several min until uniformity, sequentially adding polypeptide components, continuously stirring for several min until uniformity, completely mixing oil, adding into main pot, continuously stirring for 3-10 min, cooling to 35 min, defoaming and filtering, and discharging.
Example 1
Experimental examples 1 to 2 and comparative examples 1 to 2 were set. The difference is that:
experimental example 1 includes: about 5% polyol, 0.105% madecassoside by weight.
Comparative example 1 includes: about 5% polyol, 0.105% 4-t-butylcyclohexanol in parts by weight.
Comparative example 2 includes: about 5% polyol, by weight, without soothing ingredients.
Experimental example 2 includes: about 15% polyol, 0.105% madecassoside by weight.
Comparative example 3 includes: about 15% by weight of polyol, 4-t-butylcyclohexanol.
Comparative example 4 includes: about 15% polyol, by weight, without soothing ingredients.
The specific formulations of experimental example 1 and comparative examples 1 to 2 are shown in table 1, and the specific formulations of experimental example 2 and comparative examples 3 to 4 are shown in table 2.
TABLE 1
TABLE 2
30 subjects are selected, the ages are 24-52 years, and the selected area is not more than 50mm 2 A suitable test device with a depth of about 1mm is prepared by adding a test object into the test device in a closed patch test method in a dosage of 0.020-0.025 ml (g), applying the test device to the back of a subject, removing the test object after 24 hours, observing skin reactions after 0.5, 24 and 48 hours respectively, and recording the results according to the skin reaction grading standard in cosmetic safety technical specification 2015 not less than, wherein the skin reaction grading standard of the skin patch test is shown in Table 3, and the test results are shown in tables 4-9.
TABLE 3 Table 3
TABLE 4 Table 4
TABLE 5
TABLE 6
TABLE 7
TABLE 8
TABLE 9
As can be seen from the results of tables 4 to 9, in example 1 and comparative examples 1 and 2, the content of the polyol is small, and both example 1 and comparative example 1 can effectively suppress the generation of the stimulus response except for comparative example 2 having no relaxing ingredient. While only example 2 still performed better when the amount of polyol was increased (due to the increased peptide content), different numbers of stimulus responders appeared in the subjects to which comparative example 3 and comparative example 4 were administered.
The results show that the known soothing ingredients are effective in suppressing irritation and that the madecassoside has a better soothing effect when the amount of polyol is greater, given the lower amount of polyol in the formulation.
Example 2
Experimental example 3 and comparative example 5 were set up, with the difference that:
experimental example 3 includes about 5% by weight of polyol, 25% by weight of oil, 4% by weight of coco-caprylate/caprate, 8% by weight of caprylic/capric triglyceride, 6% by weight of white pool (LIMNANTHES ALBA) seed oil, and 7% by weight of isononyl isononanoate.
Comparative example 5 includes about 5% polyol by weight, 30% oil by weight, 6% coco-caprylate/caprate by weight, 8% caprylic/capric triglyceride by weight, 7% white pool (LIMNANTHES ALBA) seed oil, 9% isononyl isononanoate by weight.
The specific formulations of experimental example 3 and comparative example 5 are shown in table 10.
Table 10
Experimental example 3 and comparative example 5 were applied to subjects, respectively, and subjects were allowed to evaluate some skin feel dimension of the product after using the product. The number of subjects was 60.
Evaluation index: a score of 1 is "very unsatisfactory"; 2 is divided into "acceptable"; 3 is classified as "more satisfactory"; 4 is classified as "very satisfactory".
The evaluation results of experimental example 3 are shown in table 11, and the evaluation results of comparative example 5 are shown in table 12.
TABLE 11
Table 12
After selecting 33 subjects, a proper amount of the products of example 3 and comparative example 5 were applied to the face, and the moisture content of the skin horny layer was measured by a skin moisture tester, and the measurement results are shown in Table 13.
TABLE 13
Experimental example 3 | Comparative example 5 | |
Basic value (mean) | 45.7 | 43.5 |
After 28 days of application (mean value) | 55.9 | 53.2 |
Difference value | 10.2 | 9.7 |
From the results in tables 11 to 13, it can be seen that the evaluation of the test subjects was equivalent to that of the test example 3 and the comparative example 5 in the formulation having a polyol content of 5%. The water content data of the horny layer of each of the experimental example 3 and the comparative example 5 was about 10.
Therefore, when the content of the polyhydric alcohol is low, the effect of adjusting the water-oil ratio is not significant for the skin feel and the adjustment of the water content of the horny layer.
Example 3
Experimental example 4 and comparative example 6 were set. The difference is that:
experimental example 4 includes about 15 parts by weight of polyol, 25% by weight of oil, 4% by weight of coco-caprylate/caprate, 8% by weight of caprylic/capric triglyceride, 6% by weight of white pool (LIMNANTHES ALBA) seed oil, and 7% by weight of isononyl isononanoate.
Comparative example 6 included about 15 parts by weight of polyol, 30% by weight of oil, 6% coco-caprylate/caprate, 8% caprylic/capric triglyceride, 7% white pool (LIMNANTHES ALBA) seed oil, 9% isononyl isononanoate, by weight.
The specific formulations of experimental example 4 and comparative example 6 are shown in table 14.
TABLE 14
Subject skin feel questionnaires were conducted and stratum corneum water content data were collected for experimental example 4 and comparative example 6 according to the method described in example 2, and the detection results are shown in tables 15 to 17.
TABLE 15
Table 16
TABLE 17
Experimental example 4 | Comparative example 6 | |
Basic value | 34.8 | 38.7 |
After 28 days of using the product | 64.2 | 47.5 |
Difference value | 29.4 | 8.8 |
From the results in tables 15 to 17, it can be seen that. When the formulation contains about 15% by weight of the polyol, the subject can obviously feel differences in terms of ductility, sticky feel, moist feel, etc. of the product when adjusting the water-to-oil ratio, specifically, when the oil content in the formulation is respectively configured to 25% and 30% (i.e., experimental example 4 and comparative example 6).
Therefore, when the weight part of the polyol in the formula is higher, the skin feel of the product can be effectively regulated by adjusting the water-oil ratio, and the water content of the horny layer is influenced.
Example 4
Experimental examples 5 to 7 and comparative example 7 were set. The difference is that:
comparative example 7 included about 15 parts by weight of polyol, 1% by weight of oil, and 1% by weight of isononyl isononanoate.
Experimental example 5 includes about 15 parts by weight of polyol, 6% by weight of oil, 2% by weight of coco-caprylate/caprate, 2% by weight of caprylic/capric triglyceride, 1% by weight of white pool (LIMNANTHES ALBA) seed oil, and 1% by weight of isononyl isononanoate.
Experimental example 6 includes about 15 parts by weight of polyol, 10% by weight of oil, 3% by weight of coco-caprylate/caprate, 3% by weight of caprylic/capric triglyceride, 2% by weight of white pool (LIMNANTHES ALBA) seed oil, and 2% by weight of isononyl isononanoate.
Experimental example 7 includes about 15 parts by weight of polyol, 15% by weight of oil, 3% by weight of coco-caprylate/caprate, 5% by weight of caprylic/capric triglyceride, 4% by weight of white pool (LIMNANTHES ALBA) seed oil, and 3% by weight of isononyl isononanoate.
The specific components are shown in Table 18.
TABLE 18
To further determine the minimum amount of oil added, example 4 will set the proportions of oil to 1%, 6%, 10%, 15%, respectively, and the statistical results are shown in tables 19 to 23. Test examples 5 to 7 and comparative example 7 were subjected to a subject skin touch survey and stratum corneum water content data were collected according to the method described in example 2, and the test results are shown in tables 19 to 23.
TABLE 19
Table 20
Table 21
Table 22
Table 23
Comparative example 7 | Experimental example 5 | Experimental example 6 | Experimental example 7 | |
Basic value | 37.9 | 35.7 | 33.5 | 30.5 |
After 28 days of using the product | 42.5 | 67.9 | 68.8 | 69.4 |
Difference value | 4.6 | 32.2 | 35.3 | 38.9 |
As can be seen from the results in tables 19 to 23, the skin feel evaluation of the subjects, particularly the extensibility, the sticky feel and the moist feel, was very satisfactory when the oil content in the formulation was 6 to 25%. The skin feel evaluation was good, the improvement in the results of the water content of the horny layer was very remarkable, and the oil content was too low in comparative example 7 (Table 22), so that both the skin feel and the water content were not good.
The examples in which the oil content was 6%, 10% and 15% showed better moisture content in the skin stratum corneum than the examples in which the oil content was 25%. The less the oil content by weight, the more moist the product, the stronger the ability to help the skin retain water.
All other embodiments, which can be made by a person skilled in the art based on the embodiments of the invention without any inventive effort, are intended to fall within the scope of the invention.
Modifications of the technical solutions described in the above embodiments or equivalent substitutions of some technical features thereof may be made by those skilled in the art; these modifications or substitutions do not depart from the essence of the corresponding technical solutions from the protection scope of the technical solutions of the embodiments of the present disclosure.
Claims (8)
1. A cosmetic composition comprising:
an oil phase and an aqueous phase containing a polyol;
the weight part of the polyol in the water phase is not less than 10%;
a soothing component configured as bisabolol, madecassoside, inositol glycerophosphate choline salt, dipotassium glycyrrhizinate, elaeagnus pungens extract, oxyphenyl propionamide benzoic acid, ginger root extract, shea butter extract, ringer (CARDIOSPERMUM HALICACABUM) flower/leaf/vine extract, and combinations thereof.
2. The composition according to claim 1, characterized in that said soothing component is configured as 0.005-0.5% by weight of madecassoside.
3. The composition according to claim 1, characterized in that said soothing ingredient is configured as 0.05-0.3% by weight of madecassoside.
4. The composition of claim 1, wherein the polyol is present in an amount of 10 to 20% by weight.
5. The composition of claim 1, wherein the polyol is configured to be 15-20% by weight.
6. The composition of claim 1, wherein the oil phase is configured to be 5-25% by weight.
7. The composition of claim 1, wherein the oil phase is configured to be 5-15% by weight.
8. A skin preparation for external use, characterized by comprising the composition according to claims 1 to 7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840131.5A CN117442537A (en) | 2022-07-18 | 2022-07-18 | Anti-wrinkle essence |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840131.5A CN117442537A (en) | 2022-07-18 | 2022-07-18 | Anti-wrinkle essence |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117442537A true CN117442537A (en) | 2024-01-26 |
Family
ID=89584176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210840131.5A Pending CN117442537A (en) | 2022-07-18 | 2022-07-18 | Anti-wrinkle essence |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117442537A (en) |
-
2022
- 2022-07-18 CN CN202210840131.5A patent/CN117442537A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102165565B1 (en) | Cosmetic composition with excellent blemish and blemishes | |
DE102009059220A1 (en) | Cosmetic composition containing at least two osmolytes with hydrating or antidegrading activity | |
US20080160114A1 (en) | Composition of Skin External Application Containing Rose Extract and Epigallocatechin Gallate(Egcg) | |
CN111166683A (en) | Fullerene anti-aging antioxidant beauty and skin care cosmetic and preparation method thereof | |
US20220218595A1 (en) | Method of using soothing cream including maca root extract as an active ingredient | |
CN111511366A (en) | Ascorbic acid and/or external composition containing salt thereof | |
CN109846740B (en) | Skin care composition and preparation method and application thereof | |
JP4088436B2 (en) | Skin preparation | |
CN113288822A (en) | Multi-dimensional anti-wrinkle composition, cosmetic composition and preparation method of cosmetic composition | |
EP1967233B1 (en) | Aqueous external preparation for the treatment of scalp | |
CN114246817A (en) | Wrinkle-removing composition and preparation method and application thereof | |
KR20190001136A (en) | Composition of face-lifting pack for improving skin condition comprising oligopeptides | |
JP2009298752A (en) | Skin care preparation composition for external use | |
CN115414293B (en) | Anti-aging composition and application thereof | |
CN114288201B (en) | Composition for removing pouch and fading black eye, and preparation method and application thereof | |
CN117442537A (en) | Anti-wrinkle essence | |
KR101681952B1 (en) | Cosmetic composition for improving skin | |
EP3443949A1 (en) | Skin mimicking emulsion | |
CN115607476A (en) | Composition with moisturizing and antioxidant effects and application thereof | |
CN115040463A (en) | Anti-wrinkle whitening composition | |
CN115400067A (en) | Skin whitening composition | |
US20170020805A1 (en) | Cordyceps containing topical skin care formulation | |
JP7305161B2 (en) | skin cosmetics | |
CN111971043A (en) | Ascorbic acid and/or external composition containing salt thereof | |
CN112370392A (en) | Green tangerine peel-containing irritation relieving composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |